590 related articles for article (PubMed ID: 27825429)
1.
Langsteger W; Rezaee A; Pirich C; Beheshti M
Semin Nucl Med; 2016 Nov; 46(6):491-501. PubMed ID: 27825429
[No Abstract] [Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of (99m)Tc MDP scintigraphy, (18)F NaF PET/CT, and (18)F FDG PET/CT for detection of skeletal metastases.
Iagaru A; Mittra E; Dick DW; Gambhir SS
Mol Imaging Biol; 2012 Apr; 14(2):252-9. PubMed ID: 21479710
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic and prognostic effectiveness of F-18 sodium fluoride PET-CT in detecting bone metastases for hepatocellular carcinoma patients.
Yen RF; Chen CY; Cheng MF; Wu YW; Shiau YC; Wu K; Hong RL; Yu CJ; Wang KL; Yang RS
Nucl Med Commun; 2010 Jul; 31(7):637-45. PubMed ID: 20389259
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
8. A Prospective Study Comparing
Löfgren J; Mortensen J; Rasmussen SH; Madsen C; Loft A; Hansen AE; Oturai P; Jensen KE; Mørk ML; Reichkendler M; Højgaard L; Fischer BM
J Nucl Med; 2017 Nov; 58(11):1778-1785. PubMed ID: 28798033
[TBL] [Abstract][Full Text] [Related]
9.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
10.
Sheikhbahaei S; Jones KM; Werner RA; Salas-Fragomeni RA; Marcus CV; Higuchi T; Rowe SP; Solnes LB; Javadi MS
Ann Nucl Med; 2019 May; 33(5):351-361. PubMed ID: 30877561
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 18F fluoride PET/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma.
Chakraborty D; Bhattacharya A; Mete UK; Mittal BR
Clin Nucl Med; 2013 Aug; 38(8):616-21. PubMed ID: 23603596
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Bone Metastases between
Wang D; Yang Y; Zeng Z; Ye J; Guo C; Huang S; Guo X; Xiao J
Contrast Media Mol Imaging; 2022; 2022():5975338. PubMed ID: 35494210
[TBL] [Abstract][Full Text] [Related]
13. Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc-MDP bone scintigraphy, using an adaptive trial design.
Gerety EL; Lawrence EM; Wason J; Yan H; Hilborne S; Buscombe J; Cheow HK; Shaw AS; Bird N; Fife K; Heard S; Lomas DJ; Matakidou A; Soloviev D; Eisen T; Gallagher FA
Ann Oncol; 2015 Oct; 26(10):2113-8. PubMed ID: 26202597
[TBL] [Abstract][Full Text] [Related]
14. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
15. Intra-individual comparison of
Bénard F; Harsini S; Wilson D; Zukotynski K; Abikhzer G; Turcotte E; Cossette M; Metser U; Romsa J; Martin M; Mar C; Saad F; Soucy JP; Eigl BJ; Black P; Krauze A; Burrell S; Nichol A; Tardif JC
Lancet Oncol; 2022 Dec; 23(12):1499-1507. PubMed ID: 36343655
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparative study of
Fonager RF; Zacho HD; Langkilde NC; Fledelius J; Ejlersen JA; Hendel HW; Haarmark C; Moe M; Mortensen JC; Jochumsen MR; Petersen LJ
Acta Oncol; 2018 Aug; 57(8):1063-1069. PubMed ID: 29447047
[TBL] [Abstract][Full Text] [Related]
17. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
[TBL] [Abstract][Full Text] [Related]
18. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
19. Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice.
Bastawrous S; Bhargava P; Behnia F; Djang DS; Haseley DR
Radiographics; 2014; 34(5):1295-316. PubMed ID: 25208282
[TBL] [Abstract][Full Text] [Related]
20. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]